Wegovy dosing schedule and what to expect Managing side effects and tips that work Pricing, delivery, and how to get started The Link Between GLP-1 Agonists and Inflammation Beyond their established metabolic effects, emerging research suggests that GLP-1 receptor agonists may possess anti-inflammatory properties
Fast Facts See the current Solicitation dates DOD is a contracting agency Component initiated topic-driven projects - Army United States Army- Navy United States Navy- Air Force United States Air Force- CBD Chemical and Biological Defense- DARPA Defense Advanced Research Projects Agency- DHA Defense Health Agency- DLA Defense Logistics Agency- DMEA Defense Microelectronics Activity- DTRA Defense Threat Reduction Agency- MDA Missile Defense Agency- NGA National Geospatial-Intelligence Agency- OSD Office of the Secretary of Defense- USSOCOM United States Special Operations Command Offers both SBIR and STTR programs Fund $2.3 Billion in SBIR/STTR topics Three scheduled Broad Agency Announcements (BAA) as well as a As Needed BAA Proposals only accepted in response to a BAA topic DOD has 2 types of topics (Specific/Focused and Open Topics)
Serious effects: Rarely you may notice unexpected changes in your body which may suggest that your body is reacting strongly to the medication or that you are allergic to it
Summary of the Saxenda Subsection (Mini-List) Once-daily GLP-1 injection with steady appetite regulation Useful for patients who prefer gentle, gradual effects Often better tolerated early in treatment than weekly agents Supports stable portion control and reduction of cravings Strong option when insurance covers liraglutide specifically Mounjaro (Tirzepatide): A Dual GIP/GLP-1 Therapy for Powerful Metabolic and Appetite Regulation Mounjaro is a once-weekly dual agonist medication that activates both GIP and GLP-1 receptors, representing a new generation of metabolic therapies with effects that extend beyond appetite regulation alone
This article walks through what we actually know about combining a 16 amino acid lipolytic peptide with a long acting GLP-1 agonist that produced 14.9% mean weight loss in STEP 1 (Wilding et al
These are the preferred choice for any protocol where medication cost is a factor, which means essentially all home GLP-1 therapy
